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Abstract
Background: To evaluate physicians’ behavior toward antimicrobials de-escala-
tion for their patients should an opportunity come into view.
Methods: A prospective observational study held in three hospitals. Data were 
obtained prospectively for ICU patients with the diagnosis of sepsis i.e. systemic 
sepsis of any source, multi-organ dysfunction syndrome, and septic shock and were 
started on broad-spectrum antimicrobial agents (BSA). Failure to de-escalate was 
considered if a known culture was available and was susceptible to a narrower 
antimicrobial agent; hitherto the treating physician did not de-escalate. Excluded 
from the study patients who were not started on BSA, were on antimicrobial pro-
phylaxis or there was no clear indication for starting BSA, also patients whom their 
microbiological diagnoses were not available or the pathogen was only susceptible 
to the initially started BSA.
Results: One hundred and nineteen patients were followed; their charts were 
reviewed. There was 69 (58%) male and 50 (42%) female with mean ages of 59.3 
and 68.6 years respectively. Eight (6.7%) patients were de-escalated to narrower 
spectrum antimicrobials. None of: APACHE II score, comorbidities, patients’outcome 
while on BSA, sepsis-predisposing clinical diagnosis and microbiological diagnosis 
significantly encourage physicians for de-escalation. The commonest initial antimi-
crobials used were Meropenem, Pipracillin/Tazobactam and Imipenem.
Conclusion: The majority of physicians did not de-escalate when it ought to be 
done. The concept of de-escalation has to be stressed upon widely among treat-
ing physicians.
Keywords: De-escalation, Broad-spectrum antimicrobials, physicians’ behavior, 
prudent antimicrobials’ use, bacterial resistance.
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Introduction
Prudent use of antimicrobials is a worldwide necessitydue tor-
apid acquisition of resistance among bacteria disabling their 
potential use. The wide spread of multidrug resistant bacteria 
urges physicians to assume prudent antimicrobial use, avoid-
ing the use of broad spectrum antimicrobials (BSA) should 
the microorganism and its antimicrobial susceptibility pattern 
are known and can be targeted with a narrower one i.e.de-
escalation. (1)
Currently there are useful BSAs available for use in the empiric 
treatment of seriously sick patients. They comprise agents of 
different classes; carbapenems, β-lactam β-lactamase inhibi-
tors, glycylcyclines, respiratory quinolones and cephalospo-
rins including the new fifth generation ceftaroline fosamil. 
Combination antimicrobials therapies also provide broad-
spectrum coverage.
Due to their activity, it is always prudent to start with BSA 
when treating seriously septic patients who are admitted to 
ICUs. However, the practice of continuing patients on BSA 
therapy should always come under scrutiny for they may 
contribute to collateral damage and increasing resistance in 
patients and community at large. (1, 2) For this reason, the 
idea of de-escalation was in place as soon as BSA was widely 
used. The idea behind de-escalation is to utilize those agents 
when initially, empirically are needed, optimizing appropri-
ate therapy in patients, however, should a microbiological 
diagnosis was made; one would de-escalate to cover that 
specific pathogen. Unfortunately many physicians reject this 
proper behavior, and are not willing to de-escalate in spite 
of a specific pathogen and its susceptibility is known. (3, 4)
After many years of introducing the idea of de-escalation, the 
aim of this study is to evaluate physicians’ attitude in this part 
of the world; whether they de-escalate from BSA agents to 
a more specific suitable agent or not when a known micro-
biological diagnosis was available for them. We plan to test 
this hypothesis of whether physicians adopt the attitude of 
de-escalation or it is just an illusion. (5) 
Materials and Methods
Setting
A multicenter prospective study held in Amman –Jordan from 
March to August 2012. It included three hospitals; two teach-
ing and one community service hospitals with total of 52 ICU 
beds, the three hospitals do not have antimicrobial restriction 
policies. The internal review boards approved the study in the 
teaching hospitals and the medical administrator approved it 
in the community hospital. Data were collected prospectively 
from patients’files who fulfill inclusion criteria; Study teams 
collected data without having any influence on patient’ man-
agement; data collection was made by medical residents and 
PharmD’s not directly involved in ICU patients care or doing 
recommendation about antimicrobial therapy, patients were 
managed by their attending physicians; internists, intensivests 
and surgeons.
Inclusions and exclusion criteria
Patients were included if they reside in ICU, carry one of 
the major sepsis syndromes such as severe community-ac-
quired pneumonia (CAP), ventilator-associated pneumonia 
(VAP), catheter-associated urinary tract infections (CAUTI), 
severe urinary tract infections (UTI), central line-associated 
blood stream infection (CLABSI), sepsis/bacteremia of un-
defined source and blood cultures were available, skin and 
skin structure infection (SSTI) intra-abdominal infection (IAI) 
and meningitis, i.e infections resulting in significant systemic 
sepsis, multiorgan dysfunction syndrome (MODS) and septic 
shock,and were started on BSA agents as mono-therapy or in 
combination. We consider failure to de-escalate, if a culture 
was available and it was susceptible to a narrower antimi-
crobial agent and the treating physician did not de-escalate. 
Excluded from the study all patients who were not started on 
BSA agents, were on antimicrobial prophylaxis or there was 
no clear indication for the use of BSA agents, also patients 
whom their microbiological diagnoses were not available 
(known to the treating physician) or the pathogen was only 
susceptible to the initially started BSA agent(s). The following 
available agents were considered as BSA agents: carbapen-
ems, β-lactam β-lactamase inhibitors, glycylcyclines, respira-
tory quinolones and the parenteral third and fourth genera-
tions cephalosporins. Combination antimicrobials therapies 
prescribed in treating seriously sick patients and intended to 
provide BSA coverage with or without vancomycin or teico-
planin were included.
Outcome measures
The primary outcome measure is to evaluate the proportion 
of physicians who de-escalated from BSA agents to an ap-
propriate pathogen-specific antimicrobial when the patho-
gen is identified in accordance with previously published 
recommendations. (6) Secondary outcome measures were if 
physicians’ behavior or attitude were influenced by patients’ 
initial improvement, comorbidities, clinical diagnosis, micro-
biological diagnosis, outcome and APACHE II score.
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Table.  Features, characteristics and results of 119 patients included in de-escalation study for patients treated in two teaching 




N (%) P value
Age mean, both genders (Years) 60 63.5 0.67@
Primary outcome measure for patients in whom physicians de-escalated from 








































 (DM, Lung Disease, Solid Malignancy, Hemato Malignancy, 
Immunosuppressive, Heart failure) 7/8 (87.5%) 85/105 81%) 0.65*

























































Outcome                      N
 Improved and discharged from ICU
Partially improved













N: number of patients available in each category and percentage (%) where appropriate
*Pearson chi square test
@ t-test for equality of means
APACHE II: Acute Physiologic and Chronic Health Evaluation score number two
BSA duration: Number of days broad spectrum antimicrobials were used on patients
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Statistical analysis
Data were uploaded to SPSS. Proportion of physicians who 
de-escalated was calculated compared with those who did 
not. In addition, to analyze secondary variables what affected 
physicians’ attitude towards de-escalation, student t-test and 
χ2 were used to demonstrate if there were differences among 
different parameters within the subgroups. P ≤ 0.05 is con-
sidered significant. 
Results
One hundred and nineteen patients’ charts were prospective-
ly reviewed. Seventy-nine (66%) of patients were recruited 
from teaching hospitals and 40 (34%) from the community 
hospital.There was 69 (58%) male and 50 (42%) female pa-
tients with mean ages of 59.3 and 68.6 years respectively.
Eight (6.7%) patients were de-escalated to narrower spec-
trum antimicrobials upon having a microbiological diagnosis. 
Patients’ APACHEII score was similar for both; de-escalation 
or not sides and no significant difference was found (p = 
0.64). The most frequent diagnosis was septicemia of un-
defined source (60), this was followed by severe CAP (38), 
UTI (13), and VA (8) patients, no significant statistical differ-
ence was found between groups on either side (p = 0.11). 
Comorbidities included: diabetes mellitus, lung disease, solid 
malignancy, hematological malignancy, Immunosuppressive 
treatment and heart failure, no significant statistical differ-
ence among groups on either side (p = 0.65).The microbio-
logical diagnosis was not significantly different between the 
two sides (p = 0.34), seven patients among those who were 
not de-escalated had candida in addition to bacterial sepsis. 
The commonest initial antimicrobials used were Meropenem 
followed by Pipracillin/Tazobactam and Imipenem. Carbap-
enem combined were used 42% of times and pipracillin/
tazobactam in 20.5%. Quinolones, were used in 24 Patients 
in either arm, vancomycin in 22 and teicoplanin in 27 pa-
tients-use, however the last three antimicrobials were used 
in combination with a carbapenem, or pipracillin/tazobactam. 
Tigecycline was used in one patient.
There was no significant statistical difference in BSA dura-
tion between those who were de-escalated versus those who 
were not, 6.75 days versus 7.72 days (p = 0.67). Patients 
outcome; improvement and discharged from ICU, partially 
improved, did not improve and those who died did not show 
significant statistical difference between the two groups (p 
= 0.92).
Discussion
The concept of de-escalation started about two decade ago 
after BSA agents largely emanated into practice and found 
useful in combating sever sepsis syndromes. A major concept 
was introduced; to use an appropriate agent “to get it right 
the first time” so that we improve therapeutic outcome while 
cutting down on resistance. (7)Nonetheless, BSA agents were 
found not devoid of flaws should an unjustified regimen, 
duration and frequency of therapeutic dosing implemented, 
where CDI, MRSA, VRE, ESBL and the relatively late KPC are 
major culprit of wide and indiscriminate use of BSA agents. 
(8, 9, 10, 11, 12)
The aim of this study is to evaluate physicians behavior toward 
de-escalation, we found that only 8 (6.7%) out of 119 physi-
cians de-escalated to narrow-spectrum antimicrobials when 
in fact the opportunity was available for them i.e. they had 
microbiological diagnoses and susceptibility pattern compat-
ible for de-escalation. Moreover, we assessed physicians at-
titude towards de-escalation whether it was modified based 
on patients’ co-morbidities, APACHE II score, underlying clini-
cal disease and microbiological findings whether gram-posi-
tive or gram-negative; none of the previous variables affected 
physicians’ behavior (p > 0.05). Patients who were on short 
or long term regimens made no difference for physicians’ 
decision regarding de-escalation (p > 0.05).
In conclusion, the vast majority of physicians are not de-
escalating when it ought to be done. The concept of de-
escalation has to be informed widely among treating phy-
sicians backed up by the hospital clinical microbiologist. A 
caveat in the study includes small number, which precludes a 
firm conclusion about the intent to de-escalate-or-not based 
on variables like co-morbidities, APACHE II score, underlying 
clinical disease and microbiological findings whether gram-
positive or gram-negative.
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